Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CT-388

ZYNERGY

Roche · Phase 2 · Not yet recruiting · Enrollment 486

NCT07589686

ArmPopulationDoseWeeksEstimandWeight change
Arm 1: Petrelintide + Enicepatide Dosing Regimen 1Obesity or overweightn/rn/rn/rn/r
Arm 2: Petrelintide + Enicepatide Dosing Regimen 2Obesity or overweightn/rn/rn/rn/r
Arm 3: Petrelintide + Enicepatide Dosing Regimen 3Obesity or overweightn/rn/rn/rn/r
Arm 4: Petrelintide-matching Placebo + EnicepatideObesity or overweightn/rn/rn/rn/r
Arm 5: Petrelintide + Enicepatide-matching PlaceboObesity or overweightn/rn/rn/rn/r
Arm 6: Petrelintide-matching Placebo + Enicepatide-matching PlaceboObesity or overweightn/rn/rn/rn/r